Tools   Select Another Resource Report Type

http://clinicaltrials.gov/ct2/show/NCT00248651

Multi-center, randomized, placebo-controlled trial evaluating the tricyclic antidepressant, amitriptyline and the selective serotonin reuptake inhibitor (SSRI), escitalopram to placebo in patients with functional dyspepsia. The purpose of this study is to determine whether amitriptyline and escitalopram are more efficacious than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidities.

Proper citation: Functional Dyspepsia Treatment Trial (RRID:SCR_006691) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT00237081

Clinical study that investigated several hundred families with two or more blood relatives with interstitial cystitis in order to understand the molecular genetic basis of this condition. The study sought to find changes in genes that are found far more commonly in family members who have interstitial cystitis than in those who do not have the disease. Identifying these genes should lead to a better understanding of the cause of interstitial cystitis. This is a national study which is conducted by telephone and mail, and in which participants could participate entirely from their home.

Proper citation: Maryland Genetics of Interstitial Cystitis (RRID:SCR_006992) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT00059202

Multi-center, placebo-controlled trial of ursodiol in primary sclerosing cholangitis (PSC). A total of 150 patients with previously untreated PSC without cirrhosis were randomly assigned to receive high doses of ursodiol (20-25 mg/kg/day) or placebo for two years. Patients underwent medical evaluation, endoscopic retrograde cholangiography, and liver biopsy before randomization and again at two-year intervals. The endpoints of therapy were progression of hepatic fibrosis, liver decompensation, liver transplantation, or death. The treatment phase of the study was stopped for futility in June 2008; however, patients continue to be followed. Ongoing mechanistic studies are underway.

Proper citation: High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (RRID:SCR_006772) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/ct2/show/study/NCT00248638

Multi-center, double-blind, placebo-controlled, intent-to-treat Phase III trial, designed to determine the effect of parenteral glutamine (GLN) dipeptide on important clinical outcomes in patients requiring surgical intensive care unit (SICU) care and parenteral nutrition (PN) after cardiac, vascular, or intestinal surgery. Patients who required PN and SICU care will receive either standard glutamine (GLN)-free PN (STD-PN) or isocaloric, isonitrogenous alanyl-glutamine dipeptide (AG)-PN until enteral feedings are established. The study will determine whether AG-PN decreases hospital mortality, nosocomial infection and other important indices of morbidity and will obtain mechanistically relevant observational data in the subjects on whether AG-PN a) increases serial blood concentrations of glutathione (GSH), heat shock proteins (HSP)-70 and -27, and glutamine; b) decreases the serum presence of the bacterial products flagellin and lipopolysaccharide (LPS) and the adaptive immune response to these mediators; and c) improves key indices of innate and adaptive immunity.

Proper citation: Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit (RRID:SCR_006806) Copy   

•   Source: SciCrunch Registry

http://diabetes.niddk.nih.gov/dm/pubs/control/index.aspx

Clinical study that showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes. EDIC is a follow-up study of people who participated in DCCT. The DCCT involved 1,441 volunteers, ages 13 to 39, with type 1 diabetes and 29 medical centers in the United States and Canada. Volunteers had to have had diabetes for at least 1 year but no longer than 15 years. They also were required to have no, or only early signs of, diabetic eye disease. The study compared the effects of standard control of blood glucose versus intensive control on the complications of diabetes. Intensive control meant keeping hemoglobin A1C levels as close as possible to the normal value of 6 percent or less. The A1C blood test reflects a person''''s average blood glucose over the last 2 to 3 months. Volunteers were randomly assigned to each treatment group. DCCT Study Findings * Intensive blood glucose control reduces risk of ** eye disease: 76% reduced risk ** kidney disease: 50% reduced risk ** nerve disease: 60% reduced risk When the DCCT ended, researchers continued to study more than 90 percent of participants. The follow-up study, called Epidemiology of Diabetes Interventions and Complications (EDIC), is assessing the incidence and predictors of cardiovascular disease events such as heart attack, stroke, or needed heart surgery, as well as diabetic complications related to the eye, kidney, and nerves. The EDIC study is also examining the impact of intensive control versus standard control on quality of life. Another objective is to look at the cost-effectiveness of intensive control. EDIC Study Findings * Intensive blood glucose control reduces risk of ** any cardiovascular disease event: 42% reduced risk ** nonfatal heart attack, stroke, or death from cardiovascular causes: 57% reduced risk

Proper citation: Diabetes Control and Complications Trial (RRID:SCR_006805) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT00271999

Randomized controlled clinical trial where subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Primary Outcome Measures: * composite of 12 month mortality and the change over 12 months in left ventricular mass by cine-MRI, * a composite of 12 month mortality and the change over 12 months in the SF-36 RAND physical health composite Secondary Outcome Measures: * cardiovascular structure/funct (change in LV mass over 12 mos), health-related QoL/phys funct (change over 12 mos in PHC), * depression / dis burden (change over 12 mos in Beck Depression Inv.), nutrition (change over 12 mos in serum albumin, cognitive funct (change over 12 mos in TrailMaking Test B), mineral metabolism (change over 12 mos in aveg pre-dialysis serum phosphorus), * clin events (rate of non-access hospital or death * hypertension, anemia

Proper citation: Frequent Hemodialysis Network Nocturnal Trial (RRID:SCR_007014) Copy   

•   Source: SciCrunch Registry

http://www.uchicagoddrcc.org/research-cores/tissue-engineering-and-cell-models-core

Core that provides services such as a repository for intestinal cell lines, Tissue Engineering Models, experimental materials, and supplies for digestive disease research.

Proper citation: University of Chicago Digestive Diseases Research Core Center Tissue Engineering and Cell Models Core (RRID:SCR_015604) Copy   

•   Source: SciCrunch Registry

https://einsteinmed.edu/centers/diabetes-research/research-areas/biomedical-cores/translational-research-core/index.html

Core services include consultation, technical support and training and mentoring in clinical and translational research methods that are specifically applicable to diabetes, its complications and related metabolic disorders. Personel provides expertise in first-in-human and mechanistic studies in integrative physiology, in clinical trials of diabetes and obesity, and in application of new technologies.

Proper citation: Einstein-Mount Sinai Diabetes Research Center Translational Research Core Facility (RRID:SCR_015068) Copy   

•   Source: SciCrunch Registry

http://drc.ucsf.edu/mouse-metabolism-core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 10,2024. Core which provides technical support for UCSF investigators to conduct metabolic studies using a 12-chambered Comprehensive Lab Animal Monitoring System (CLAMS), an EchoMRI, and Dual energy X-ray absorptiometry, which together allow measurement of food intake, water intake, motor activities, core temperature, and body composition in live mice. It also helps to identify emerging technologies that will enhance multiple research programs and coordinates the acquisition and maintenance of those facilities.

Proper citation: University of California San Francisco Diabetes Research Center Mouse Metabolism Core (RRID:SCR_015101) Copy   

•   Source: SciCrunch Registry

https://www.baderc.org/cores/cbmcore/

Services provided include tissue preparation, embedding and sectioning for electron microscopy, use of electron microscope and photography of thin sections, immunogold staining for electron microscopy, preparation and incubation of samples (cells and tissues) for immunofluorescence microscopy, confocal microscopy and digital imaging.

Proper citation: Boston Area Diabetes Endocrinology Research Center Cell Biology and Morphology Core Facility (RRID:SCR_015069) Copy   

•   Source: SciCrunch Registry

https://diabetes.ucsf.edu/drc-islet

Core that enables clinical and basic research that analyzes the function of isolated pancreatic islets. It coordinates and delivers purified human islets to investigators when research need matches the availability of a human pancreas.

Proper citation: University of California San Francisco Diabetes Research Center Islet Production Core Facility (RRID:SCR_015106) Copy   

•   Source: SciCrunch Registry

https://diabetes.ucsf.edu/drc-microscopy

Core that consolidates, enhances and disseminates Diabetes Center resources and expertise in tissue and cell imaging technologies. Confocal fluorescence, widefield fluorescence, high throughput fluorescence and brightfield microscopes are available directly within the DRC Microscopy Core. Image quantification and analysis is performed at dedicated workstations.

Proper citation: University of California San Francisco Diabetes Research Center Microscopy Core Facility (RRID:SCR_015103) Copy   

•   Source: SciCrunch Registry

http://drc.ucsf.edu/lentiviral-rnai-core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on November 5,2024. Core that provides reagents, equipment, training, supervision, and monitoring of investigators wishing to ensure the proper compliance with biosafety containment required for lentiviral-based research, lentiviral preparation services for investigators, and education on RNAi experimentation, through the lentiviral core website, and through protocols available at the facility.

Proper citation: University of California San Francisco Diabetes Research Center Lentiviral RNAi Core Facility (RRID:SCR_015104) Copy   

•   Source: SciCrunch Registry

http://www.baderc.org/cores/molbioCore.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 24,2024. Core that provides services for DNA sequencing and oligonucleotide synthesis, as well as support for projects that require research laboratory automation, such as siRNA screens and transcript abundance profiling. It also offers experimental design and advice for automation and high throughput screening of siRNA collections based on the Ambion siRNA collection.

Proper citation: Boston Area Diabetes Endocrinology Research Center Molecular Biology (RRID:SCR_015079) Copy   

•   Source: SciCrunch Registry

http://www.uab.edu/shp/drc/animal-physiology-core-links

Core that provides diabetes researches with diabetes related phenotyping in small animal models. Their services offered include the assessment of body composition, energy balance, glucose homeostasis, cardiovascular assessment, imaging, and transgenic animals models.

Proper citation: University of Alabama at Birmingham Diabetes Research Center Animal Physiology Core Facility (RRID:SCR_015110) Copy   

•   Source: SciCrunch Registry

https://www.derc.cuimc.columbia.edu/services/flow-cytometry-and-cell-sorting-core

Core which assists investigators to quantify and phenotypically characterize cell populations that contribute to the metabolic, immunologic and developmental programs of diabetes and its complications; and to purify populations of cells of relevance to diabetes and its complications.

Proper citation: Columbia Diabetes Research Center Flow Cytometry and Cell Sorting Core Facility (RRID:SCR_015078) Copy   

•   Source: SciCrunch Registry

https://diabetes.med.umich.edu/affiliated-centers/michigan-diabetes-research-center-mdrc/cores/administration

Administration Core of the Michigan Diabetes Research Center (MDRC) provides leadership, infrastructure, and resources to support and enhance diabetes research, including the translation of scientific discoveries from bench to bedside. Establishes, promotes, and enhances multidisciplinary and collaborative basic biomedical and clinical research among member investigators studying diabetes, its complications, and related endocrine and metabolic disorders.

Proper citation: Michigan Diabetes Research Center Administrative Core Facility (RRID:SCR_015115) Copy   

•   Source: SciCrunch Registry

http://www.baderc.org/cores/IsletCore.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 23,2024.Core which provides islets to the local diabetes research community in the Boston area. They collaborate with researchers nationally to provide nonhuman primate (NHP) islets for research.

Proper citation: Boston Area Diabetes Endocrinology Research Center Pancreatic Islet (RRID:SCR_015073) Copy   

•   Source: SciCrunch Registry

https://diabetes.med.umich.edu/affiliated-centers/michigan-diabetes-research-center-mdrc/cores/molecular-genetics

Core that provides services related to the application of genetic methodologies to research related to diabetes. Services include generation of targeted genetic mouse models, using CRISPR/Cas9 system in mouse or rat embryos, generation of specialty viral vectors, specialty viral reagents, and specialty mouse models.

Proper citation: Michigan Diabetes Research Center Molecular Genetics Core Facility (RRID:SCR_015119) Copy   

•   Source: SciCrunch Registry

http://depts.washington.edu/diabetes/administrative-core/

Core facility that supports the Diabetes Research Center in its primary mission to enhance research, education and training in diabetes, obesity and related disorders at the University of Washington and in the Greater Seattle area. The Core coordinates and manages programs, evaluates Center activities, and performs other duties.

Proper citation: University of Washington Diabetes Research Center Administrative Core (RRID:SCR_015124) Copy   

•   Source: SciCrunch Registry